MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
The drug is priced at Rs 2000 for a course of 40 tablets
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Subscribe To Our Newsletter & Stay Updated
